Categories Earnings, Other Industries

Earnings preview: What’s on the cards for Biocept in Q2

Biocept (NASDAQ: BIOC) is set to release its earnings results for the second quarter of 2019 on Monday after the market closes. The commercial-stage molecular oncology diagnostics company is likely to post a narrower loss backed by higher revenue.

The company’s revenue-generating efforts are focused on medical oncologists, surgical oncologists, pulmonologists, pathologists, and providing laboratory services utilizing both circulating tumor cell (CTC) and ctDNA testing. It also includes licensing and selling its proprietary testing.

The research and development expenses are expected to rise for the second quarter due primarily to costs associated with the development of new individual assays and automation, as well as validation of our Target Selector NGS Lung assay panel under the collaboration with Thermo Fisher Scientific.

diagnostics
Image for representation only. Courtesy: Michal Jarmoluk from Pixabay

Biocept is likely to see an increase in physician usage of its liquid biopsy tests for breast cancer monitoring using CTC. This quarter’s performance could be benefited by the Target Selector NGS Lung, its multi-gene liquid biopsy panel specifically developed to detect and monitor actionable biomarkers associated with lung cancer.

The company intends to grow its business by directly offering medical oncologists, surgical oncologists, pulmonologists, pathologists and other physicians its Target-Selector liquid biopsy CTC and ctDNA assays.

Also read: Progenics Q2 earnings review

Analysts expect the company to report a loss of $0.19 per share on revenue of $1.3 million for the second quarter. In comparison, during the previous year quarter, Biocept posted a loss of $2.70 per share on revenue of $822,000. The company has missed analysts’ expectations thrice in the past four quarters.

For the first quarter, Biocept reported a narrower loss helped by higher revenue as well as lower costs and expenses. Biocept accessioned 1,325 total samples in the first quarter of 2019, a 13% increase from last year, and accessioned 1,155 billable samples, up 7% from a year ago.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Comments

  1. Pingback: engineering jobs
  2. Pingback: Coursework
  3. Pingback: social networks
  4. Pingback: Fiverr Earn
  5. Pingback: Fiverr Earn
  6. Pingback: Fiverr Earn
  7. Pingback: Fiverr Earn
  8. Pingback: Fiverr Earn
  9. Pingback: fiverrearn.com
  10. Pingback: fiverrearn.com
  11. Pingback: fiverrearn.com
  12. Pingback: hair loss
  13. Pingback: fiverrearn.com
  14. Pingback: fiverrearn.com
  15. Pingback: fiverrearn.com
  16. Pingback: bitcoin
  17. Pingback: sorority jewelry
  18. Pingback: clima sarasota
  19. Pingback: micro frenchie
  20. Pingback: future university
  21. Pingback: future university
  22. Pingback: golf cart mexico
  23. Pingback: bulldogs puppy
  24. Pingback: fue
  25. Pingback: FUE
  26. Pingback: FUE
  27. Pingback: FUE
  28. Pingback: Moving assistance
  29. Pingback: Classic Books 500
  30. Pingback: FiverrEarn
  31. Pingback: FiverrEarn
  32. Pingback: FiverrEarn
  33. Pingback: FiverrEarn
  34. Pingback: FiverrEarn
  35. Pingback: partners
  36. Pingback: brain supplements
  37. Pingback: Economics
  38. Pingback: french bulldog
  39. Pingback: Tips
  40. Pingback: FiverrEarn
  41. Pingback: FiverrEarn
  42. Pingback: live sex cams
  43. Pingback: live sex cams
  44. Pingback: FiverrEarn
  45. Pingback: FiverrEarn
  46. Pingback: FiverrEarn
  47. Pingback: FiverrEarn
  48. Pingback: FiverrEarn
  49. Pingback: FiverrEarn
  50. Pingback: FiverrEarn
  51. Pingback: FiverrEarn
  52. Pingback: FiverrEarn
  53. Pingback: FiverrEarn
  54. Pingback: FiverrEarn
  55. Pingback: FiverrEarn
  56. Pingback: wix seo expert
  57. Pingback: graphic design
  58. Pingback: gold
  59. Pingback: Kuliah Termurah
  60. Pingback: FiverrEarn
  61. Pingback: FiverrEarn
  62. Pingback: cheap sex cams
  63. Pingback: fullersears.com
  64. Pingback: dog probiotics
  65. Pingback: live sex cams
  66. Pingback: live sex cams
  67. Pingback: live sex cams
  68. Pingback: live sex cams
  69. Pingback: freeze dried candy
  70. Pingback: freeze dried
  71. Pingback: rare breed-trigger
  72. Pingback: 늑대닷컴
  73. Pingback: allgame
  74. Pingback: 918kiss
  75. Pingback: หวย24
  76. Pingback: Makeup highlighter
  77. Pingback: pg slot
  78. Pingback: regles 421
  79. Pingback: cybersécurité
  80. Pingback: megagame
  81. Pingback: ItMe.Xyz
  82. Pingback: FB URL Shortener
  83. Pingback: MasumINTL
  84. Pingback: itme.xyz
  85. Pingback: ItMe.Xyz

Comments are closed.

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top